[go: up one dir, main page]

EE200300355A - Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks - Google Patents

Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks

Info

Publication number
EE200300355A
EE200300355A EEP200300355A EEP200300355A EE200300355A EE 200300355 A EE200300355 A EE 200300355A EE P200300355 A EEP200300355 A EE P200300355A EE P200300355 A EEP200300355 A EE P200300355A EE 200300355 A EE200300355 A EE 200300355A
Authority
EE
Estonia
Prior art keywords
neublastin
methods
polymer conjugates
conjugates
polymer
Prior art date
Application number
EEP200300355A
Other languages
English (en)
Inventor
W. Y. Sah Dinah
Blake Pepinsky R.
Ann Borjack-Sjodin Paula
S. Miller Stephan
Rossomando Anthony
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300355A publication Critical patent/EE200300355A/et
Publication of EE05537B1 publication Critical patent/EE05537B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
EEP200300355A 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks EE05537B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
EE200300355A true EE200300355A (et) 2003-10-15
EE05537B1 EE05537B1 (et) 2012-04-16

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300355A EE05537B1 (et) 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks

Country Status (35)

Country Link
EP (2) EP1862475A1 (et)
JP (2) JP4259868B2 (et)
KR (2) KR100960063B1 (et)
CN (1) CN1500095B (et)
AR (1) AR035077A1 (et)
AT (1) ATE365748T1 (et)
AU (1) AU2002247037B2 (et)
BG (1) BG66393B1 (et)
BR (1) BR0206852A (et)
CA (1) CA2436407C (et)
CY (1) CY1106886T1 (et)
CZ (1) CZ20032080A3 (et)
DE (1) DE60220879T2 (et)
DK (1) DK1355936T3 (et)
EA (1) EA009771B1 (et)
EE (1) EE05537B1 (et)
ES (1) ES2289091T3 (et)
GE (1) GEP20063916B (et)
HU (1) HU228973B1 (et)
IL (2) IL156941A0 (et)
IS (1) IS2867B (et)
MX (1) MXPA03006805A (et)
MY (1) MY143685A (et)
NO (1) NO332150B1 (et)
NZ (1) NZ527863A (et)
PL (1) PL211162B1 (et)
PT (1) PT1355936E (et)
RS (1) RS50857B (et)
SG (1) SG149685A1 (et)
SI (1) SI1355936T1 (et)
SK (1) SK288123B6 (et)
TR (1) TR200301208T2 (et)
UA (2) UA82983C2 (et)
WO (1) WO2002060929A2 (et)
ZA (1) ZA200305733B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
CA2436407C (en) * 2001-02-01 2011-08-30 Biogen, Inc. Polymer conjugates of neublastin and methods of using same
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CA2442159C (en) * 2001-03-28 2011-08-23 Biogen, Inc. Treatment using neublastin polypeptides
BRPI0306993B8 (pt) * 2002-01-18 2021-05-25 Biogen Idec Inc polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
MEP43808A (en) * 2003-01-31 2011-02-10 Biogen Idec Inc Polymer conjugates of mutated neublastin
DK1897552T3 (da) 2003-04-18 2009-10-05 Biogen Idec Inc Polymer-konjugeret glycosyleret neublastin
JP5623685B2 (ja) 2003-06-10 2014-11-12 エヌエスゲーネ・アクティーゼルスカブ ニューブラスチンの改良された分泌
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
EP2238983B1 (en) 2004-08-19 2014-07-23 Biogen Idec MA Inc. Neublastin variants
AU2005277227B2 (en) * 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
HRP20110487T1 (hr) 2006-09-15 2011-08-31 Creabilis Therapeutics S.R.L. Polimerni konjugati hmgb1 box-a i varijanti hmgb1 box-a
ES2476253T3 (es) * 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
AU2012323995B2 (en) * 2011-11-02 2016-06-09 Genentech, Inc. Overload and elute chromatography
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
JP2002531128A (ja) * 1998-12-09 2002-09-24 アムジエン・インコーポレーテツド 神経栄養因子grnf4
CA2436407C (en) * 2001-02-01 2011-08-30 Biogen, Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
WO2002060929A2 (en) 2002-08-08
CY1106886T1 (el) 2012-09-26
HU228973B1 (en) 2013-07-29
ZA200305733B (en) 2005-02-23
EP1355936A2 (en) 2003-10-29
IL156941A0 (en) 2004-02-08
BG108111A (bg) 2004-12-30
EP1355936B1 (en) 2007-06-27
JP2009039135A (ja) 2009-02-26
ES2289091T3 (es) 2008-02-01
UA82983C2 (ru) 2008-06-10
PL372101A1 (en) 2005-07-11
HK1057759A1 (en) 2004-04-16
GEP20063916B (en) 2006-09-11
HUP0500637A2 (hu) 2005-09-28
DE60220879T2 (de) 2008-03-06
EA200300852A1 (ru) 2004-06-24
WO2002060929A3 (en) 2003-03-06
UA100967C2 (ru) 2013-02-25
CN1500095A (zh) 2004-05-26
EE05537B1 (et) 2012-04-16
SK9712003A3 (en) 2004-01-08
ATE365748T1 (de) 2007-07-15
KR100872807B1 (ko) 2008-12-09
YU61003A (sh) 2006-05-25
SI1355936T1 (sl) 2007-12-31
NO332150B1 (no) 2012-07-09
EP1862475A1 (en) 2007-12-05
TR200301208T2 (tr) 2005-05-23
NO20033441D0 (no) 2003-08-01
SG149685A1 (en) 2009-02-27
JP4259868B2 (ja) 2009-04-30
MXPA03006805A (es) 2003-11-13
RS50857B (sr) 2010-08-31
HUP0500637A3 (en) 2010-01-28
PL211162B1 (pl) 2012-04-30
DK1355936T3 (da) 2007-10-29
AU2002247037B2 (en) 2007-08-16
JP2005503763A (ja) 2005-02-10
IS2867B (is) 2014-02-15
KR100960063B1 (ko) 2010-05-31
IL156941A (en) 2008-11-03
MY143685A (en) 2011-06-30
KR20080098662A (ko) 2008-11-11
IS6879A (is) 2003-07-17
PT1355936E (pt) 2007-09-28
EA009771B1 (ru) 2008-04-28
JP4423338B2 (ja) 2010-03-03
CZ20032080A3 (cs) 2003-10-15
AR035077A1 (es) 2004-04-14
KR20030074766A (ko) 2003-09-19
BG66393B1 (bg) 2013-11-29
BR0206852A (pt) 2005-05-03
NZ527863A (en) 2006-09-29
DE60220879D1 (de) 2007-08-09
CA2436407C (en) 2011-08-30
NO20033441L (no) 2003-10-01
CN1500095B (zh) 2010-06-16
CA2436407A1 (en) 2002-08-08
SK288123B6 (sk) 2013-09-03

Similar Documents

Publication Publication Date Title
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
NO20040778L (no) Superabsorberende polymer
NO20025580D0 (no) Medisinsk anordning
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
AR028622A1 (es) Derivados de tropano utiles en terapia
DK1284764T3 (da) Medicinsk apparat
ATE468324T1 (de) Pharmazeutische zusammensetzung
EE200300355A (et) Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
FI20011671A0 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
MA26998A1 (fr) Conjugues peg de hgt-nk4
DE60137941D1 (de) Polymerzusammensetzung
DE60217539D1 (de) Leichtathletikschuh
ATE366128T1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60008489D1 (de) Lösbarer Endanschlag
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (en) MEDICAL COMPOSITIONS
FR2816398B3 (fr) Fronde perfectionnee
FIU20000507U0 (fi) Clinikit DiagnoPacks ja Openkit-konsepti

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160125